Neuroleptic malignant syndrome

Abstract

INTRODUCTION The neuroleptic malignant syndrome (NMS) is a variably defined disorder (Table 1) that was first reported in 1960 [1], seven years after the introduction of dopamine-blocking antipsychotic drugs. It did not attract much clinical attention until the English publication of a review paper in 1980 [2]. Since then it has been the subject of a large number of reports.